Literature DB >> 29437787

REGγ Controls Hippo Signaling and Reciprocal NF-κB-YAP Regulation to Promote Colon Cancer.

Qingwei Wang1, Xiao Gao1, Tong Yu2, Lei Yuan1, Jie Dai1, Weicang Wang1, Geng Chen1, Chan Jiao1, Wang Zhou3, Quan Huang3, Long Cui2, Pei Zhang4, Robb E Moses5, Jianhua Yang6, Fengyuan Chen7, Junjiang Fu8, Jianru Xiao9, Lei Li1, Yongyan Dang10, Xiaotao Li10,5.   

Abstract

Purpose: Colorectal cancer is one of the most commonly diagnosed cancers closely associated with inflammation and hyperactive growth. We previously demonstrated a regulatory circuit between the proteasome activator REGγ and NF-kappaB (NF-κB) during colon inflammation, known to be important in the development of colitis-associated cancer as well as sporadic colorectal cancer. How the inflammatory microenvironment affects the Hippo pathway during colorectal cancer development is largely unknown.Experimental Design: Here, we used REGγ-deficient colon cancer cell lines, REGγ knockout mice, and human colorectal cancer samples to identify the novel molecular mechanism by which REGγ functions as an oncoprotein in the development of colorectal cancer.
Results: REGγ can directly interact with Lats1 and promote its degradation, which facilitates Yes-associated protein (YAP) activation in colon cancer cells. REGγ deficiency significantly attenuated colon cancer growth, associated with decreased YAP activity. Suppression of tumor growth due to REGγ depletion was overcome by constitutively active YAP. Surprisingly, reciprocal activation of the YAP and NF-κB pathways was observed in human colon cancer cells. REGγ overexpression was found in over 60% of 172 colorectal cancer specimens, highly correlating with the elevation of YAP and p65. Postoperative follow-up revealed a significantly lower survival rate in patients with concomitantly high expression of REGγ, YAP, and p-p65.Conclusions: REGγ could be a master regulator during colorectal cancer development to promote YAP signaling and reinforce cross-talks between inflammation and growth pathways, and REGγ might be a new marker for prognosis of colorectal cancer patients. Clin Cancer Res; 24(8); 2015-25. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID: 29437787     DOI: 10.1158/1078-0432.CCR-17-2986

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  Tubule-Specific Mst1/2 Deficiency Induces CKD via YAP and Non-YAP Mechanisms.

Authors:  Chunhua Xu; Li Wang; Yu Zhang; Wenling Li; Jinhong Li; Yang Wang; Chenling Meng; Jinzhong Qin; Zhi-Hua Zheng; Hui-Yao Lan; Kingston King-Lun Mak; Yu Huang; Yin Xia
Journal:  J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 10.121

2.  Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.

Authors:  Liangfang Yao; Yang Xuan; Haiyang Zhang; Bo Yang; Xinglong Ma; Tianzhen Wang; Tianyuan Meng; Wenshe Sun; Haibin Wei; Xueqing Ma; Robb Moses; Jianru Xiao; Pei Zhang; Chao Ge; Jinjun Li; Lei Li; Xiaotao Li; Jinbao Li; Bianhong Zhang
Journal:  Oncogene       Date:  2020-11-23       Impact factor: 9.867

3.  Yes-Associated Protein 1 as a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis.

Authors:  Luo Zhang; Xing Song; Xiaodong Li; Changping Wu; Jingting Jiang
Journal:  Biomed Res Int       Date:  2018-11-14       Impact factor: 3.411

4.  ZNF280A Promotes Proliferation and Tumorigenicity via Inactivating the Hippo-Signaling Pathway in Colorectal Cancer.

Authors:  Xu Wang; Di Sun; Jiandong Tai; Si Chen; Sen Hong; Lei Wang
Journal:  Mol Ther Oncolytics       Date:  2019-01-25       Impact factor: 7.200

Review 5.  CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs.

Authors:  Andrew Sulaiman; Sarah McGarry; Xianghui Han; Sheng Liu; Lisheng Wang
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

6.  LATS1/2 suppress NFκB and aberrant EMT initiation to permit pancreatic progenitor differentiation.

Authors:  Caitlin M Braitsch; D Berfin Azizoglu; Yadanar Htike; Haley R Barlow; Ulrike Schnell; Christopher P Chaney; Thomas J Carroll; Ben Z Stanger; Ondine Cleaver
Journal:  PLoS Biol       Date:  2019-07-19       Impact factor: 8.029

7.  Downregulated miR-585-3p promotes cell growth and proliferation in colon cancer by upregulating PSME3.

Authors:  Chunmei Liu; Juan Yang; Han Wu; Jun Li
Journal:  Onco Targets Ther       Date:  2019-08-14       Impact factor: 4.147

Review 8.  A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.

Authors:  Maria Grzes; Magdalena Oron; Zuzanna Staszczak; Akanksha Jaiswar; Magdalena Nowak-Niezgoda; Dawid Walerych
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

9.  The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells.

Authors:  Xiao Gao; Qingwei Wang; Ying Wang; Jiang Liu; Shuang Liu; Jian Liu; Xingli Zhou; Li Zhou; Hui Chen; Linian Pan; Jiwei Chen; Da Wang; Qing Zhang; Shihui Shen; Yu Xiao; Zhipeng Wu; Yiyun Cheng; Geng Chen; Syeda Kubra; Jun Qin; Lan Huang; Pei Zhang; Chuangui Wang; Robb E Moses; David M Lonard; Bert W O' Malley; Fuad Fares; Bianhong Zhang; Xiaotao Li; Lei Li; Jianru Xiao
Journal:  Nat Commun       Date:  2020-08-06       Impact factor: 14.919

Review 10.  Pectin Oligosaccharides Ameliorate Colon Cancer by Regulating Oxidative Stress- and Inflammation-Activated Signaling Pathways.

Authors:  Haidong Tan; Wei Chen; Qishun Liu; Guojun Yang; Kuikui Li
Journal:  Front Immunol       Date:  2018-06-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.